Coriolis Pharma Opens New ATMP Formulation Development Facilities

Coriolis Pharma, a provider of formulation research and development services for biopharmaceuticals and vaccines, has opened its new ATMP development facilities under biosafety level S2 (BSL2 / S2).

After one year of re-construction, the new facilities in close proximity to Coriolis’ headquarters in Martinsried will increase Coriolis’ capabilities for ATMP development. Formulation development for ATMPs, including cell culture activities, particle characterization, particle identification and forensic, analytical ultracentrifugation and a lyophilization development center will be available all under biosafety level 2, for Coriolis’ clients and partners.

“The new location with innovative labs and offices will be able to accommodate in the future more than 100 scientific employees,” said Michael Wiggenhorn, CEO, Coriolis Pharma.” With this expansion, we will meet the increasing demand for formulation development and analytical characterization of ATMPs.”

Advanced therapy medicinal products (ATMPs) are booming, but ATMP formulations are still far from advanced. Similar to mRNA vaccines, ATMPs either have a very short shelf life (hours to days) or require (ultra) cold storage conditions. A tailored formulation development program, also exploring lyophilization as an option, can remarkably improve this situation.

In 2018, Coriolis started strengthening its scientific expertise and services for ATMPs with a dedicated formulation unit for ATMPs and scientific collaborations that resulted in several peer-reviewed scientific publications. The opening of the new facilities marks the next step in the organic growth of the company.

Gerhard Sax, business unit manager ATMP, Coriolis Pharma, said, “Having all our S2 activities in a dedicated and tailored facility increases the efficiency of our work procedures and creates a knowledge-hub for our ATMP projects. But what excites me the most is that we now have enough space to test and implement even more new and emerging technologies right under S2.”